Epidermal growth factor receptor inhibition strategies in oncology

  1. P M Harari
  1. University of Wisconsin Medical School, Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue K4/332, Madison, Wisconsin 53792, USA
  1. (Requests for offprints should be addressed to P M Harari; Email: harari{at}humonc.wisc.edu)
  1. Figure 1

    Schematic diagram of the four ErbB family members and their ligands. Numbers denote the degree (expressed as a percentage) of homology relative to ErbB1/EGFR. With the exception of the kinase-deficient ErbB3, there exists a high degree of homology in the tyrosine kinase domain. Adapted with permission from Harari et al.(2003).

  2. Figure 2

    Simplified schematic illustration of the EGFR pathway highlighting potential downstream cellular and tissue effects of EGFR signaling inhibition. The action site for EGFR inhibitors is depicted for mAbs and TKIs. Adapted with permission from Harari & Huang (2001).

  3. Figure 3

    Mutations identified in the EGFR tyrosine kinase domain (red) conferring sensitivity to gefitinib in non-small cell lung cancer patients. Adapted with permission from Lynch et al.(2004).

| Table of Contents